ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On July 11, 2018, AcelRx Pharmaceuticals, Inc. (the “Company”) filed a preliminary prospectus supplement with the U.S. Securities and Exchange Commission (the “SEC”), to Rule 424(b)(5) (the “Preliminary Prospectus Supplement”), in which it disclosed that, although it has not finalized its financial statements for the quarter ended June 30, 2018, it expects to report that it had approximately $50 million of cash, cash equivalents and short-term investments as of June 30, 2018. This estimate of the Company’s cash, cash equivalents and short-term investments as of June 30, 2018 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures and review of the financial statements by the Company’s independent registered public accounting firm. Additional information and disclosure would be required for a more complete understanding of our financial position and results of operations as of June 30, 2018.
This Item 2.02 of this report contains forward-looking statements, including, without limitation, statements relating to the Company’s cash position as of June 30, 2018. These forward-looking statements are based upon the Company’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks related to changes in estimated cash position based on the completion of the Company’s financial statement closing procedures and the review by the Company’s independent registered public accounting firm of such financial statements, and other risks detailed in the Company’s filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
The information contained in this Item 2.02 shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 to this Current Report shall not be incorporated by reference into any filing with the SEC under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.